← News

One dose, two Phase 3 trials, two verdicts

Bayer took one dose of asundexian into two Phase 3 trials. It lost to apixaban in AF. Last week it won FDA approval in stroke.

FDA approved it as Sunharbo on 9 November: 50 mg once daily with antiplatelets after a recent mild-to-moderate non-cardioembolic stroke or high-risk TIA. Ischemic stroke 6.2% vs 8.4% on placebo. In AF, the same-dose trial stopped early: stroke or systemic embolism 1.3% vs 0.4% on apixaban.

Key points

  • Phase 2 in AF was a bleeding study: 50 mg gave 92% factor XIa inhibition at trough
  • Phase 2 in stroke showed no dose-response on its primary endpoint
  • Both Phase 3s tested 50 mg only; no AF indication

Our read: hitting the target beat placebo, not apixaban; against an active comparator we would not take one dose to Phase 3 on target engagement and bleeding alone.

If Phase 2 hits the target but shows no dose-response, how many doses go into Phase 3?

In detail

Stroke: better than placebo, on top of antiplatelets

Hazard ratio 0.74. FDA approval 9 November 2026, 50 mg once daily. Major bleeding similar overall, higher above 75 years and in the first 90 days.

Atrial fibrillation: worse than apixaban

Same 50 mg once daily. The trial was stopped early on the data monitoring committee's advice. Major bleeding was lower: 0.2% vs 0.7%.

Hitting the target is not beating the comparator

  • Phase 2 in AF was a bleeding study: 50 mg gave 92% factor XIa inhibition at the lowest drug level, 94% at peak
  • Phase 2 in stroke tested 10, 20 and 50 mg and showed no dose-response on its primary endpoint
  • Against an active comparator, we would not take one dose into Phase 3 on target engagement and bleeding data alone

Sources

Download the slides (PDF)Discuss it on LinkedIn
Cover slide: One dose, two Phase 3 trials, two verdicts
The slides, as a PDF

Is this question in front of your program?

A 15-minute call is enough to tell whether modeling can move it. A fixed proposal follows within 48 hours.